JP2025508840A5 - - Google Patents

Info

Publication number
JP2025508840A5
JP2025508840A5 JP2024550216A JP2024550216A JP2025508840A5 JP 2025508840 A5 JP2025508840 A5 JP 2025508840A5 JP 2024550216 A JP2024550216 A JP 2024550216A JP 2024550216 A JP2024550216 A JP 2024550216A JP 2025508840 A5 JP2025508840 A5 JP 2025508840A5
Authority
JP
Japan
Prior art keywords
cells
polypeptide
arg2
polypeptide according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508840A (ja
Filing date
Publication date
Priority claimed from GBGB2202547.2A external-priority patent/GB202202547D0/en
Priority claimed from GBGB2213372.2A external-priority patent/GB202213372D0/en
Application filed filed Critical
Priority claimed from PCT/EP2023/054568 external-priority patent/WO2023161346A1/en
Publication of JP2025508840A publication Critical patent/JP2025508840A/ja
Publication of JP2025508840A5 publication Critical patent/JP2025508840A5/ja
Pending legal-status Critical Current

Links

JP2024550216A 2022-02-24 2023-02-23 アルギナーゼ2ワクチン Pending JP2025508840A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2202547.2A GB202202547D0 (en) 2022-02-24 2022-02-24 Arginase 2 vaccine
GB2202547.2 2022-02-24
GBGB2213372.2A GB202213372D0 (en) 2022-09-13 2022-09-13 Arginase 2 vaccine
GB2213372.2 2022-09-13
PCT/EP2023/054568 WO2023161346A1 (en) 2022-02-24 2023-02-23 Arginase 2 vaccine

Publications (2)

Publication Number Publication Date
JP2025508840A JP2025508840A (ja) 2025-04-10
JP2025508840A5 true JP2025508840A5 (cg-RX-API-DMAC7.html) 2026-03-04

Family

ID=85415242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550216A Pending JP2025508840A (ja) 2022-02-24 2023-02-23 アルギナーゼ2ワクチン

Country Status (9)

Country Link
US (1) US20250161422A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482518A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508840A (cg-RX-API-DMAC7.html)
KR (1) KR20240159833A (cg-RX-API-DMAC7.html)
CN (1) CN119110729A (cg-RX-API-DMAC7.html)
AU (1) AU2023223567A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250919A1 (cg-RX-API-DMAC7.html)
IL (1) IL315164A (cg-RX-API-DMAC7.html)
WO (1) WO2023161346A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
PL3522905T3 (pl) 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
AU2019201463A1 (en) * 2018-03-09 2019-09-26 Nantomics, Llc Srm/mrm assays for profiling tumor tissue
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
US20210382068A1 (en) * 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
GB201818576D0 (en) 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides

Similar Documents

Publication Publication Date Title
Cao et al. The roles of tissue resident macrophages in health and cancer
Nowak et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents
US6328956B1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
JP2022095926A (ja) 乳癌再発の予防のためのワクチン
Oki et al. Heat shock protein-based cancer vaccines
Taniura et al. Immunogenic chemotherapy in two mouse colon cancer models
CN108392633A (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
He et al. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
Younes et al. Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
CN115702927A (zh) 一种广谱性肿瘤疫苗增效的组合物
Toda Glioma stem cells and immunotherapy for the treatment of malignant gliomas
JPH09511737A (ja) 免疫治療剤とその使用
Yang et al. Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant
JP2022507373A5 (cg-RX-API-DMAC7.html)
WO2017177908A1 (zh) Pd-l1和pd-l2重组蛋白及其用途
Boliukh et al. Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines
AU725218B2 (en) Immunogenic TLP composition
MX2007006717A (es) Peptidos de alfa timocina como adyuvantes en vacunas contra el cancer.
di Pietro et al. Oncophage®(vitespen®)-Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?
He et al. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2
EP0466813A1 (en) Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
CN112402612B (zh) 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法
Nemunaitis et al. 630. A phase 2 randomized study of GM-CSF gene-modified autologous tumor cell immunotherapy (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC)
Niu Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy